Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular…
HERE'S WHAT THE ?? STOCK MARKET LOOKED LIKE TODAY Up 8: Bristol-Myers Squibb $BMY +4.9% Adobe $ADBE +3.9% Hilton $HLT +3.8% Eli Lilly $LLY +3.6% Air Products $APD +3.3% Amgen $AMGN +3.3% Merck $MRK +3.3% Regeneron $REGN +3.3% Down 8: Comfort Systems $FIX -4.6% Howmet Aerospace…
Healthcare leading the $SPX $SPY today. The sector is up ~2% on the day and the S&P 500 leaders today are: $LLY $MRK $UNH $ABBV $AMGN $PFE $BMY $GILD $CVS $REGN
$BMY from our gapper alert bot https://t.co/0S0s2IrNqq
$PRME ?Potential $BMY Milestones Exceed 5x Market Cap for a Revolutionary Platform This is a very long-duration investment for me. I entered around $1.50 and averaged up a bit around $3. I plan to DCA another significant block if and when management raises capital, depending on…
28 analysts rate BMY Hold on consensus.
Consensus price target: $65.42 (+6.41% upside from $61.48)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Massacesi Cristian EVP,Chief Med Offr,Head of Dev | Sep 9, 2026 | Sale | 6,249 | $403.5K |
| Holzer Phil M SVP and Controller | Aug 25, 2026 | Sale | 500 | $33.75K |
| Elkins David V EVP, Chief Financial Officer | Apr 1, 2026 | Sale | 4,481 | $278.05K |
| Elkins David V EVP, Chief Financial Officer | Apr 1, 2026 | Sale | 25,519 | $1.57M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $48.2B | -0.22% | $7.05B |
| 2024 | $48.3B | +7.32% | $-8.95B |
| 2023 | $45.01B | -2.5% | $8.03B |
Stock data for BMY: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics